1Y1D
 
 | | Crystal structure of transthyretin in complex with iododiflunisal | | Descriptor: | 2',4'-DIFLUORO-4-HYDROXY-5-IODO-1,1'-BIPHENYL-3-CARBOXYLIC ACID, Transthyretin | | Authors: | Gales, L, Macedo-Ribeiro, S, Arsequell, G, Valencia, G, Saraiva, M.J, Damas, A.M. | | Deposit date: | 2004-11-18 | | Release date: | 2005-07-26 | | Last modified: | 2023-08-23 | | Method: | X-RAY DIFFRACTION (1.7 Å) | | Cite: | Human transthyretin in complex with iododiflunisal: structural features associated with a potent amyloid inhibitor.
Biochem.J., 388, 2005
|
|
3B56
 | |
1CE6
 | | MHC CLASS I H-2DB COMPLEXED WITH A SENDAI VIRUS NUCLEOPROTEIN PEPTIDE | | Descriptor: | PROTEIN (HUMAN BETA-2 MICROGLOBULIN), PROTEIN (MHC CLASS I H-2DB HEAVY CHAIN), PROTEIN (SENDAI VIRUS NUCLEOPROTEIN), ... | | Authors: | Tormo, J, Jones, E.Y. | | Deposit date: | 1999-03-17 | | Release date: | 1999-03-26 | | Last modified: | 2023-08-09 | | Method: | X-RAY DIFFRACTION (2.9 Å) | | Cite: | Crystal structures of two H-2Db/glycopeptide complexes suggest a molecular basis for CTL cross-reactivity.
Immunity, 10, 1999
|
|
1QLF
 | | MHC CLASS I H-2DB COMPLEXED WITH GLYCOPEPTIDE K3G | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, GLYCEROL, HUMAN BETA-2-MICROGLOBULIN, ... | | Authors: | Tormo, J, Jones, E.Y. | | Deposit date: | 1999-08-30 | | Release date: | 1999-09-01 | | Last modified: | 2023-12-13 | | Method: | X-RAY DIFFRACTION (2.65 Å) | | Cite: | Crystal Structures of Two H-2Db/Glycopeptide Complexes Suggest a Molecular Basis for Ctl Cross-Reactivity
Immunity, 10, 1999
|
|
7ACU
 | |
3FCB
 | |
3FC8
 | |
6EOY
 | | Transthyretin in complex with 4-(1,3-Benzothiazol-2-yl)-2-methylaniline | | Descriptor: | 4-(1,3-benzothiazol-2-yl)-2-methyl-aniline, Transthyretin | | Authors: | Leite, J.P, Gales, L. | | Deposit date: | 2017-10-10 | | Release date: | 2021-10-06 | | Last modified: | 2024-01-17 | | Method: | X-RAY DIFFRACTION (1.38 Å) | | Cite: | Targeting transthyretin in Alzheimer's disease: Drug discovery of small-molecule chaperones as disease-modifying drug candidates for Alzheimer's disease.
Eur.J.Med.Chem., 226, 2021
|
|
